Inhibition of PLCβ1 signaling pathway regulates methamphetamine self-administration and neurotoxicity in rats

https://doi.org/10.1016/j.fct.2021.111970Get rights and content

Highlights

What is already known:

  • Angiotensin II receptor type 1 (AT1R) antagonist, candesartan cilexetil (CAN) effectively reduced METH SA and reinstatement. Furthermore, overexpression of specific miR-219a-5p targeting AT1R regulated METH SA and reinstatement.

What this study adds:

  • Blockade of AT1R attenuates METH-induced neurotoxicity and cognitive deficits, possibly through the PLCβ1-PKCα-CREB signalling pathway in rats. PLCβ1 blockade significantly decreased METH SA and cue-/drug-reinstatement.

What is the clinical significance:

  • These results further support the potential utility of PLCβ1 antagonist to treat METH use disorder.

Abstract

Studies have shown that the central renin–angiotensin system is involved in neurological disorders. Our previous studies have demonstrated that angiotensin II receptor type 1 (AT1R) in the brain could be a potential target against methamphetamine (METH) use disorder. The present study was designed to investigate the underlying mechanisms of the inhibitory effect of AT1R on various behavioural effects of METH. We first examined the effect of AT1R antagonist, candesartan cilexetil (CAN), on behavioural and neurotoxic effects of METH. Furthermore, we studied the role of phospholipase C beta 1 (PLCβ1) blockade behavioural and neurotoxic effects of METH. The results showed that CAN significantly attenuated METH-induced behavioral disorders and neurotoxicity associated with increased oxidative stress. AT1R and PLCβ1 were significantly upregulated in vivo and in vitro. Inhibition of PLCβ1 effectively alleviated METH-induced neurotoxicity and METH self-administration (SA) by central blockade of the PLCβ1 involved signalling pathway. PLCβ1 blockade significantly decreased the reinforcing and motivation effects of METH. PLCβ1 involved signalling pathway, as well as a more specific role of PLCβ1, involved the inhibitory effects of CAN on METH-induced behavioural dysfunction and neurotoxicity. Collectively, our findings reveal a novel role of PLCβ1 in METH-induced neurotoxicity and METH use disorder.

Introduction

Long-term METH exposure has been shown to produce a wide range of psychological problems, including psychological distress, depression, suicide, anxiety, violent behaviours, and psychosis (Darke et al., 2008; Lecomte et al., 2018; Ma et al., 2018; McKetin et al., 2018; Potvin et al., 2018). Significant cognitive dysfunctions, including attention, prospective memory, retrospective memory, and executive operations, have also been suggested to be associated with long-term use of METH and interfere with daily function (Henry et al., 2010; Newton et al., 2004; Rendell et al., 2009; Simon et al., 2000, 2002). In line with the clinical studies, METH administration produces a multitude of behavioural abnormalities, including object and spatial memory impairments in the animals (Potvin et al., 2018; Rogers et al., 2008). Neurotoxicity is suggested to be one of the main mechanisms underlying METH-induced cognitive deficits. Exposure to high-dose METH leads to neuronal or glial toxicity in striatum, prefrontal cortex and amygdala in both rats and mice (Mark et al., 2004; Tata and Yamamoto, 2008; Veerasakul et al., 2016; Zhu et al., 2006). These comorbid disorders may further deteriorate the consequences of METH use disorder, indicating the need for “trans-diagnostic treatment approaches” (Bernheim et al., 2016; Hartel-Petri et al., 2017). Due to the lack of effective pharmacological treatment for METH use disorder, the medications specifically targeting the improvement of cognitive impairments may be promising to treat METH use disorder (Bernheim et al., 2016; Moszczynska and Callan, 2017; Soares and Pereira, 2019; Zhong et al., 2016).

Angiotensin II (Ang II) acts as a neuropeptide, neuromodulator, neurotransmitter, and neurohormone in the central nervous system (CNS) (Bali and Jaggi, 2013). It has been suggested to have a significant impact on several neurological and psychological disorders, such as Huntington's chorea, epilepsy, Alzheimer's disease, Parkinson's disease, and depression (Bali and Jaggi, 2013; Hariharan et al., 2014; Kehoe et al., 2019; Krasniqi and Daci, 2019; Labandeira-Garcia et al., 2016; Vian et al., 2017; Wright and Harding, 2019; Wright et al., 2008). Due to the high co-morbidity of METH use disorder and psychological disorders, some studies have investigated the role of angiotensin II in drug use disorder. Acute and chronic cocaine treatment increases angiotensin converting enzyme (ACE) activity and messenger RNA (mRNA) expression in the striatum and frontal cortex of rats (Visniauskas et al., 2012). ACE inhibitor, captopril, produces analgesic effects and can affect morphine-induced conditioned place preference and withdrawal signs in rats (Alaei and Hosseini, 2007). A growing number of studies have specifically focused the role of Ang II in the behavioural effects of drugs of abuse. For example, repeated METH administration upregulates AT1R mRNA and protein expression in the striatum of mice (Jiang et al., 2018). An AT1R blocker, telmisartan, has shown to attenuate METH-induced hyperlocomotion in mice (Jiang et al., 2018). The interaction between AT1R and amphetamine has been shown to contribute to long-term repeated amphetamine administration in rats (Marchese et al., 2016). In addition, the development of oxidative/inflammatory conditions could be modulated by AT1R in rats exposed to amphetamine (Marchese et al., 2020).

Our previous studies have also demonstrated that AT1R blockade significantly decreased METH self-administration (SA) and cue-/drug-induced reinstatement, in conjunction with counter-regulation of dopamine receptors and AT1R (Xu et al., 2019). The current study was designed to further explore the mechanism underlying the inhibitory effects of AT1R on the behavioural effects of METH, focusing on the phospholipase C β1 (PLCβ1)-cAMP response element-binding protein (CREB) signalling pathway. Firstly, the effect of AT1R blockade on various behavioural and neurotoxic effects induced by METH was investigated both in vivo and in vitro. Moreover, the role of PLCβ1-PKCα-CREB signalling pathway in the behavioural and neurotoxic effect of METH was examined. The potential impact of PLCβ1 blockade on the reinforcing and motivational effect of METH was finally studied, using METH SA and drug/cue-induced reinstatement animal model.

Section snippets

Drugs

METH was dissolved in 0.9% saline (0.9% NaCl). CAN (TCV-116) was purchased from Tokyo Chemical Industry (Tokyo, Japan) and dissolved in dimethyl sulfoxide (DMSO). U73122, a PLCβ1 inhibitor, was purchased from Med Chem Express (HY-13419, Shanghai, China). U73122 was dissolved in 20 μl of Tween 20 and resuspended it in saline solution. CAN and U73122 was administered via oral gavage and intraperitoneal (i.p.) injection, respectively.

Animals

Male Sprague-Dawley (SD) rats (8–10 weeks old, weighting between

Experiment 1: the effect of ATR1 blockade by CAN on the behavioral and neurotoxic effects of METH in rats

The procedures of Experiment 1 are summarized in Fig. 1A. DMSO and CAN was administered 2 h before all behavioral testing. Saline and METH was given 30 min prior to all behavioral testing. During the locomotor adaptation period, the rectal temperature was daily recorded. Based on the distance travelled during the last day of adaptation period, rats were divided into five groups (Saline+10CAN, Saline + DMSO, METH + DMSO, METH+5CAN and METH+10CAN). Immediately before the animals were placed into

Statistics

Data are presented as mean ± SD. P < 0.05 was considered as statistically significant. Body temperature is presented as temperature change from baseline (in °C) and analyzed by one-way analysis of variance (ANOVA) with Bonferroni's post hoc multiple comparisons test. For the locomotor activity test, two-way repeated measures ANOVA was used with Bonferroni's post hoc multiple comparisons to examine the effect of drug treatment on total distance travelled per session across days. For NOR test,

The effect of ATR1 blockade by CAN on the behavioral effects of METH in rats

One-way ANOVA analysis showed a significant group effect on body temperature changes from the baseline (F(4, 30) = 7.807, p < 0.001). Further post hoc analysis showed that the changes of body temperature of the METH + DMSO group was significantly higher than that of the Saline + DMSO group (Fig. 1B; p < 0.01). The body temperature changes from the baseline of both METH+5CAN (Fig. 1B; p < 0.01) and METH+10CAN (Fig. 1B; p < 0.001) groups were significantly lower than METH + DMSO group. There were

Discussion

The present study demonstrated that PLCβ1-PKCα-CREB signaling pathway played an important role in the inhibitory effect of ATR1 on various METH-mediated behavioral effects. Firstly, ATR1 inhibition by CAN significantly attenuated METH-induced behavioral disorders and neurotoxicity associated with increased oxidative stress. Furthermore, the data revealed that PLCβ1-PKCα-CREB signaling pathway, as well as a more specific role of PLCβ1, involved the inhibitory effects of AT1R on METH-induced

Author contributions

X.X. and Y.L. designed the study and prepared the manuscript; X.X., R.F., Y.R., M. X., J.H. performed all the in vivo and vitro experiments studies; M.C., X.L. participated in the analysis of the experiments. W.Z. and Y.L. contributed to the experimental design and revised the manuscript. All authors read and approved the final version of the manuscript.

CRediT authorship contribution statement

Xing Xu: designed the study and prepared the manuscript, performed all the in vivo and vitro experiments studies, All authors read and approved the final version of the manuscript. Runyue Fan: performed all the in vivo and vitro experiments studies, All authors read and approved the final version of the manuscript. Yanqian Ruan: performed all the in vivo and vitro experiments studies, All authors read and approved the final version of the manuscript. Mengjie Xu: performed all the in vivo and

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Acknowledgments

Funding: This work was supported in part by the National Natural Science Foundation of China (81671323; 81971247), Zhejiang Provincial Key R & D Plan 2019 (2020C03064), Ningbo R & D Plan (20181ZDYF020172), National Social Science Foundation Key Programs (18ZDA215), and the Program for Innovative Research Team in Ningbo City (2015C110026).

References (57)

  • T. Lecomte et al.

    The prevalence of substance-induced psychotic disorder in methamphetamine misusers: a meta-analysis

    Psychiatr. Res.

    (2018)
  • Z. Li et al.

    Prophylactic angiotensin type 1 receptor antagonism confers neuroprotection in an aged rat model of postoperative cognitive dysfunction

    BBRC (Biochem. Biophys. Res. Commun.)

    (2014)
  • E.D. London et al.

    Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging

    Brain Res.

    (2015)
  • J. Ma et al.

    Relationship between the duration of methamphetamine use and psychotic symptoms: a two-year prospective cohort study

    Drug Alcohol Depend.

    (2018)
  • R. McKetin et al.

    First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine

    Schizophr. Res.

    (2018)
  • S. Potvin et al.

    Cognitive deficits in individuals with methamphetamine use disorder: a meta-analysis

    Addict. Behav.

    (2018)
  • E.J. Shin et al.

    PKCdelta inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment

    Neurochem. Int.

    (2011)
  • E.J. Shin et al.

    Role of oxidative stress in methamphetamine-induced dopaminergic toxicity mediated by protein kinase Cdelta

    Behav. Brain Res.

    (2012)
  • E. Trofimiuk et al.

    Candesartan, angiotensin II type 1 receptor blocker is able to relieve age-related cognitive impairment

    Pharmacol. Rep.

    (2018)
  • B. Visniauskas et al.

    Cocaine administration increases angiotensin I-converting enzyme (ACE) expression and activity in the rat striatum and frontal cortex

    Neurosci. Lett.

    (2012)
  • X. Wang et al.

    Chitosan attenuates dibutyltin-induced apoptosis in PC12 cells through inhibition of the mitochondria-dependent pathway

    Carbohydr. Polym.

    (2016)
  • J.W. Wright et al.

    Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets

    Prog Neurobiol

    (2008)
  • P. Zhang et al.

    The effects of early exposure to MK-801 during environmental enrichment on spatial memory, methamphetamine self-administration and cue-induced renewal in rats

    Behav. Brain Res.

    (2019)
  • N. Zhong et al.

    The cognitive impairments and psychological wellbeing of methamphetamine dependent patients compared with health controls

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2016)
  • J.P. Zhu et al.

    Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice

    Neuroscience

    (2006)
  • A. Chen et al.

    Molecular mechanisms of group I metabotropic glutamate receptor mediated LTP and LTD in basolateral amygdala in vitro

    Psychopharmacology (Berl)

    (2017)
  • M. Dai et al.

    Inhibition of JNK signalling mediates PPARalpha-dependent protection against intrahepatic cholestasis by fenofibrate

    Br. J. Pharmacol.

    (2017)
  • S. Darke et al.

    Major physical and psychological harms of methamphetamine use

    Drug Alcohol Rev.

    (2008)
  • Cited by (0)

    View full text